Nuvectis Pharma, Inc. - Common Stock (NQ:NVCT)

18.48 -0.09 (-0.48%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Nuvectis Pharma, Inc. - Common Stock

< Previous 1 2 3 Next >

Here are the top movers in Tuesday's session. ↗

June 30, 2026

Via Chartmill

Top movers analysis in the middle of the day on 2026-06-30: top gainers and losers in today's session. ↗

June 30, 2026

Via Chartmill

Traders are paying attention to the gapping stocks in Tuesday's session. ↗

June 30, 2026

Via Chartmill

Tuesday's pre-market session: top gainers and losers ↗

June 30, 2026

Via Chartmill

Recap: Nuvectis Pharma Q3 Earnings ↗

November 08, 2023

Via Benzinga

Wondering what's happening in today's after-hours session? ↗

June 29, 2026

Via Chartmill

Keep an eye on the top gainers and losers in Wednesday's session. ↗

June 24, 2026

Via Chartmill

Here are the top movers in Wednesday's session. ↗

June 24, 2026

Via Chartmill

Nuvectis (NVCT) Q2 Loss Widens 43% ↗

August 05, 2025

Via The Motley Fool

Discover the top movers in Thursday's pre-market session. ↗

July 31, 2025

Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

July 31, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 27, 2025

Via Benzinga

Nuvectis Pharma's NXP900: Could This Revolutionary Cancer "Inactivator" Transform Oncology Treatment?

May 05, 2025

Truffle Pigs Blog Highlights Potential Game-Changing Cancer Therapy with Unique Mechanism of Action

Via News Direct

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

February 03, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

November 14, 2024

Via Benzinga

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug ↗

November 14, 2024

Nuvectis Pharma reports mixed Phase 1b results for NXP800 in ovarian cancer, showing antitumor activity and improved safety with adjusted dosing.

Via Benzinga

S&P 500 Moves Lower; US Crude Oil Inventories Increase ↗

November 14, 2024

Via Benzinga

Topics Stocks

Dow Falls Over 100 Points; US Producer Prices Rise In October ↗

November 14, 2024

Via Benzinga

Topics Stocks

US Stocks Edge Lower; Cisco Earnings Top Views ↗

November 14, 2024

Via Benzinga

From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update

October 28, 2024

The report covers Nuvectis (NASDAQ: NVCT) alongside notable similar precision oncology players such as Nuvalent ($6.6B) and Summit Therapeutics ($15B).

Via News Direct

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 16, 2024

Via Benzinga

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

September 19, 2024

Summit Therapeutics' rise could signal emerging opportunities in precision oncology such Nuvectis Pharma (NASDAQ: NVCT), Silexion (NASDAQ:SLXN), and Scorpion leading the charge.

Via News Direct

Could Nuvectis Pharma be the Next Summit Therapeutics? A New Report Highlights NXP900's Approach to NSCLC Treatment

September 16, 2024

Report spotlights Nuvectis Pharma's (NASDAQ: NVCT) NXP900 as a potential game-changer in NSCLC treatment, noting its unique mechanism targeting SRC/YES1 kinases and promising preclinical data

Via News Direct

Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data

August 29, 2024

Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data

Via News Direct

7 Penny Biotech Stocks to Triple Your Investment ↗

May 28, 2024

Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns.

Via InvestorPlace

NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024 ↗

May 07, 2024

NVCT stock results show that Nuvectis Pharma beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

5 Healthcare Stocks to Buy for 2024 ↗

April 02, 2024

Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up.

Via InvestorPlace

Topics Artificial Intelligence

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 14, 2024

Via Benzinga

NVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023 ↗

March 05, 2024

NVCT stock results show that Nuvectis Pharma missed analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

January 18, 2024

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.